On Friday, food manufacturing Company
Naturally Splendid Enterprises Ltd. (TSX-V.NSP, OTCQB: NSPDF, Forum) released a response to Health Canada regarding its joint venture
Plasm Pharmaceutical. The Company stated that this is considered a formality as Plasm Pharmaceutical continues to prepare for a phase 2 clinical trial for a potential COVID-19 treatment utilizing the target drug Cavaltinib.
To read the response in full, click
here.
In a recent
update on strategy for investors, NSP explained that Cavaltinib is a curcumin extract derived from a Biologic patented technology. The Company also unveiled its new corporate website -
www.naturallysplendid.com.
FULL DISCLOSURE: Naturally Splendid Enterprises Ltd. is a client of Stockhouse Publishing.